Advancements in Early Cancer Detection
Dec 07, 2021 8:00 AM
Jin Yun, PharmD, Medical Science Liaison, GRAIL
Advancements in Early Cancer Detection

When cancer is detected early, the survival rates and patient outcomes are much better. Unfortunately, 71% of cancer deaths are due to cancers that currently have no recommended screening. These cancers are usually found at a late stage, once a patient presents with physical symptoms. New technology, studied at the Mayo Clinic, Cleveland Clinic, Dana Farber Institute, UCSF, and elsewhere, has shown promising results in detecting many different cancers in early stages through a simple blood draw, allowing patients to screen for many cancers at once and physicians to intervene earlier when cancer is detected. 

Jin Yun is a pharmacist and received his Doctor of Pharmacy degree from the University of Michigan.  Prior to his current role with Grail, he worked at various pharmaceutical and biotech companies covering hematology and oncology.  Earlier in his career he served as a clinical pharmacist in the PBM and managed care world most recently with Blue Shield of California working in the market strategy and analytics department supporting pharmacy services for employers, unions, health systems, and government organizations.